- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Large Cap High Growth Potential
Global Pharmaceuticals & Biotech Large Cap High Growth Potential
UPDATED May 13, 2024
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
51 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
BGNE | US$162.17 | -0.2% | -32.5% | US$17.0b | US$267.01 | PS6.1x | E60.4% | n/a | ||
TEVA | US$16.88 | 20.1% | 109.2% | US$19.1b | US$17.34 | PS1.2x | E40.4% | 0% | ||
BMRN | US$80.50 | -1.9% | -15.4% | US$15.3b | US$110.24 | PE74.4x | E29.8% | n/a | ||
GILD | US$67.54 | 3.2% | -13.8% | US$84.1b | US$82.93 | PE173.5x | E36.5% | 4.6% | ||
REC | €50.50 | 0.3% | 10.0% | €10.4b | €52.24 | PE26.8x | E10.4% | 2.4% | ||
NTRA | US$103.33 | 6.3% | 98.1% | US$12.7b | US$121.63 | PS10.5x | E69.8% | n/a | ||
4502 | JP¥4,102.00 | -0.6% | -8.6% | JP¥6.4t | JP¥4,762.44 | PE44.7x | E20.2% | 4.8% | ||
GSK | UK£18.10 | 4.4% | 23.2% | UK£73.8b | UK£20.32 | PE16.5x | E12.2% | 3.2% | ||
NOVN | CHF93.07 | 5.6% | 0.6% | CHF189.9b | CHF98.28 | PE23x | E9.9% | 3.5% | ||
MEDP | US$389.27 | -2.9% | 84.6% | US$12.0b | US$423.17 | PE38.5x | E13.8% | n/a | ||
BNTX | US$92.72 | -0.7% | -14.1% | US$22.3b | US$114.44 | PE183.3x | E20.8% | n/a | ||
ILMN | US$112.77 | -5.2% | -45.0% | US$18.0b | US$156.10 | PS4x | E63.1% | n/a | ||
VTRS | US$11.36 | -3.9% | 21.2% | US$13.5b | US$12.33 | PB0.7x | E9.7% | 4.2% | ||
AVTR | US$24.29 | -2.3% | 19.2% | US$16.5b | US$27.77 | PE63.5x | E35.0% | n/a | ||
HZNP | US$116.30 | 0.06% | 82.8% | US$26.6b | US$116.50 | PE60.8x | E16.4% | n/a | ||
4568 | JP¥5,422.00 | -1.5% | 16.0% | JP¥10.4t | JP¥5,853.33 | PE51.8x | E18.6% | 1.1% | ||
ROG | CHF227.80 | 4.3% | -19.9% | CHF183.9b | CHF279.39 | PE15.8x | E8.6% | 4.2% | ||
4503 | JP¥1,510.50 | -3.0% | -30.6% | JP¥2.7t | JP¥2,009.38 | PE158.9x | E30.4% | 4.9% | ||
CSL | AU$279.92 | 1.6% | -9.1% | AU$135.3b | AU$302.14 | PE36.2x | E14.7% | 1.3% | ||
BAYN | €29.38 | 4.7% | -44.9% | €28.9b | €36.90 | PB0.9x | E46.3% | 0.4% | ||
INCY | US$57.60 | 6.5% | -13.0% | US$12.9b | US$73.35 | PE17.4x | E17.8% | n/a | ||
VRTX | US$429.93 | 6.8% | 23.3% | US$110.9b | US$462.09 | PE27.6x | E10.3% | n/a | ||
RVTY | US$105.55 | 2.7% | -8.4% | US$13.0b | US$123.61 | PE71x | E26.6% | 0.3% | ||
NOVO B | kr.909.90 | 6.9% | 56.6% | kr.4.1t | kr.908.65 | PE45.4x | E13.3% | 1.0% |